Evaluation of Safety, Tolerability, and Biological Activity of TQS-168 in Patients with Amyotrophic Lateral Sclerosis: A Phase 1B Randomized, Placebo-Controlled Study

The primary objective of this study is to evaluate the **safety**, **tolerability**, and **biological activity** of TQS-168 in subjects with **Amyotrophic Lateral Sclerosis** (ALS). This is clinically relevant as ALS is a progressive neurodegenerative disease with limited treatment options, and understanding the safety profile and potential biological effects of TQS-168 could contribute to the development of new therapeutic strategies.

The clinical trial involves participants diagnosed with **amyotrophic lateral sclerosis**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population, including any key inclusion or exclusion criteria, have not been disclosed by the sponsor.

The clinical trial is a **randomized**, **double-blind**, and **placebo-controlled** study designed to evaluate the safety, tolerability, and biological activity of TQS-168 in subjects with **amyotrophic lateral sclerosis**. The trial is categorized as a Phase 1b study and is conducted across multiple centers. The estimated recruitment start date is September 1, 2023, with an anticipated end date of July 31, 2024. The trial involves a series of structured visits, beginning with an inclusion visit where participants are screened for eligibility based on predefined criteria. This is followed by a series of follow-up visits, which are scheduled at regular intervals to monitor the participants' response to the treatment and to assess any adverse effects. The study concludes with an end-of-study visit, where final assessments are conducted to evaluate the overall outcomes of the trial.

Participants are expected to be involved in the study for the entire duration, from the initial screening to the end-of-study visit, unless specific conditions necessitate early termination. Such conditions may include the occurrence of significant adverse events, withdrawal of consent, or any other protocol-defined criteria that compromise the safety or well-being of the participant. The trial's design ensures that neither the participants nor the investigators are aware of the treatment assignments, maintaining the integrity of the double-blind methodology. The study's duration and visit schedule are structured to provide comprehensive data on the investigational product's effects, contributing valuable insights into its potential therapeutic benefits for individuals with amyotrophic lateral sclerosis.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on September 1, 2023, with an estimated completion date of July 31, 2024. Efficacy will be evaluated using predefined endpoints, although specific parameters or endpoints are not detailed in the provided data. The trial will adhere to rigorous methods for measuring, collecting, and analyzing efficacy data, consistent with Phase 3 standards. The trial's design and execution will ensure that efficacy assessments are conducted systematically and objectively, in alignment with clinical trial protocols.